Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lupus Survival Is Improving Slowly

Will Boggs, MD  |  October 30, 2017

“This report paves the way for future studies to identify persons of specific race/ethnicity, sex, age group, and of socioeconomic status and behavior patterns living in certain counties who are at the highest risk of death from lupus,” he says. “So, the counties could focus their resources to target these high-risk populations. This concept is called ‘precision public health.’”

“The good news is that both lupus death rate and lupus death rate relative to non-lupus death rate (ratio) have begun to decrease since the late 1990s at a relatively high pace: (the) lupus death rate has decreased 2.7% every year since 1999, and the ratio has decreased 1.2% every year since 1998,” Dr. Singh says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Assuming that this recent decrease is not due to some unforeseen factor, such as a rapid decrease in the incidence of lupus over the past two decades, our results suggest that the management strategies that we are taking seem to be helping lupus patients,” he says. “These management strategies include an aggressive approach to monitor lupus disease activity, judicious use of induction and maintenance regimen of immunosuppressive medications, including mycophenolate, judicious use of corticosteroids, use of hydroxychloroquine, and screening for complications such as atherosclerosis.”

Dr. Luis Ines, director of the lupus clinic at Centro Hospitalar Universitario de Coimbra, in Portugal, tells Reuters Health by email, “Clinical progress in SLE is lagging behind other diseases as a whole. Outcomes can probably be improved by extending access to best standard of care to more patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“There is an unmet need for new drugs and treatment strategies in SLE, that is becoming larger as compared to other diseases,” he says.

Dr. Cezar Caldas from Centro Universitario do Estado do Para (CESUPA), Belem, Brazil, recently reported on SLE mortality there. He tells Reuters Health by email, “As in Brazil, there are regional discrepancies, possibly related to socioeconomic conditions and access to health services. It should be a warning to the authorities, understanding that there are subpopulations that require more attention to reach better health levels.”

Dr. Caldas recommends giving “attention to these subpopulations, especially those older than 65 years, where thinking about the diagnosis of SLE may be more difficult.”


Reference

  1. Yen EY, Shaheen M, Woo JMP, et al. 46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: A nationwide population-based study. Ann Intern Med. 2017 Oct 30. doi: 10.7326/M17-0102.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:mortalitymortality ratesSLEsystemic lupus erythematosus (SLE)

Related Articles

    A 46-Year Study Traces the Lupus Death Rate from 1968–2013

    September 20, 2018

    A study published in Annals of Internal Medicine in December 2017 looked at trends in lupus mortality over a 46-year period. The researchers say they set out to close some knowledge gaps. “There [was] a knowledge gap relating to the large differences we see in death rates from one study to another, which could have…

    Studies Highlight Risk of Damage from Lupus Treatments

    April 20, 2017

    WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences